ArticleNeoplasia (New York, N.Y.)2012

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Christel Larbouret et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.